Cargando…
Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING:...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685727/ https://www.ncbi.nlm.nih.gov/pubmed/35246454 http://dx.doi.org/10.1136/ebmental-2021-300355 |
_version_ | 1784835575901061120 |
---|---|
author | Joseph, Rebecca M Jack, Ruth H Morriss, Richard Knaggs, Roger David Butler, Debbie Hollis, Chris Hippisley-Cox, Julia Coupland, Carol |
author_facet | Joseph, Rebecca M Jack, Ruth H Morriss, Richard Knaggs, Roger David Butler, Debbie Hollis, Chris Hippisley-Cox, Julia Coupland, Carol |
author_sort | Joseph, Rebecca M |
collection | PubMed |
description | BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING: Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. PARTICIPANTS: 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. MAIN OUTCOME MEASURES: Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. RESULTS: Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. CONCLUSIONS: There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. CLINICAL IMPLICATIONS: Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm. |
format | Online Article Text |
id | pubmed-9685727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-96857272022-11-25 Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records Joseph, Rebecca M Jack, Ruth H Morriss, Richard Knaggs, Roger David Butler, Debbie Hollis, Chris Hippisley-Cox, Julia Coupland, Carol Evid Based Ment Health Adult Mental Health BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING: Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. PARTICIPANTS: 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. MAIN OUTCOME MEASURES: Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. RESULTS: Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. CONCLUSIONS: There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. CLINICAL IMPLICATIONS: Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm. BMJ Publishing Group 2022-11 2022-03-04 /pmc/articles/PMC9685727/ /pubmed/35246454 http://dx.doi.org/10.1136/ebmental-2021-300355 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Adult Mental Health Joseph, Rebecca M Jack, Ruth H Morriss, Richard Knaggs, Roger David Butler, Debbie Hollis, Chris Hippisley-Cox, Julia Coupland, Carol Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title | Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title_full | Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title_fullStr | Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title_full_unstemmed | Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title_short | Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records |
title_sort | association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using uk electronic health records |
topic | Adult Mental Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685727/ https://www.ncbi.nlm.nih.gov/pubmed/35246454 http://dx.doi.org/10.1136/ebmental-2021-300355 |
work_keys_str_mv | AT josephrebeccam associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT jackruthh associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT morrissrichard associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT knaggsrogerdavid associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT butlerdebbie associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT hollischris associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT hippisleycoxjulia associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords AT couplandcarol associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords |